N-(3-((2-((4-sulfamoylphenyl)amino)furo[3,2-d]pyrimidine-4-yl)oxy)phenyl)acrylamide | 1353553-02-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-(3-((2-((4-sulfamoylphenyl)amino)furo[3,2-d]pyrimidine-4-yl)oxy)phenyl)acrylamide
• 英文别名: N-(3-((2-((4-sulfamoylphenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide；N-[3-[2-(4-sulfamoylanilino)furo[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
• CAS: 1353553-02-2
• 化学式: C₂₁H₁₇N₅O₅S
• 分子量: 451.462
• InChiKey: ZOCCRHHRSWEJJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  158
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• [EN] NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY<br/>[FR] NOUVEAUX DÉRIVÉS FUSIONNÉS DE PYRIMIDINE POUR L'INHIBITION DE L'ACTIVITÉ TYROSINE KINASE
  申请人：HANMI HOLDINGS CO LTD

  公开号：WO2011162515A2

  公开（公告）日：2011-12-29

  The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.

  本发明涉及一种新型融合嘧啶衍生物，具有对酪氨酸激酶的抑制活性，并且涉及一种制备预防或治疗癌症、肿瘤、炎症性疾病、自身免疫疾病或免疫介导疾病的药物组合物，其包含该新型融合嘧啶衍生物作为活性成分。
• NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY
  申请人：Cha Mi Young

  公开号：US20130116213A1

  公开（公告）日：2013-05-09

  The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.

  本发明涉及一种新型融合嘧啶衍生物，具有对酪氨酸激酶的抑制活性，以及一种药物组合物，其作为活性成分用于预防或治疗癌症、肿瘤、炎症性疾病、自身免疫疾病或免疫介导性疾病。
• NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHD3ITION OF TYROSINE KINASE ACTIVITY
  申请人：Hanmi Science Co., Ltd.

  公开号：EP2585470A2

  公开（公告）日：2013-05-01
• USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER
  申请人：Del Mar Pharmaceuticals

  公开号：EP3125920A2

  公开（公告）日：2017-02-08
• EP3125920B1
  申请人：——

  公开号：EP3125920B1

  公开（公告）日：2020-12-23